lifestyle.realie.org

Author: Ipsen Pharma

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

March 18, 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America

March 12, 2026
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

March 9, 2026
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

February 27, 2026
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

February 12, 2026
Ipsen nomme Peter Guenter au sein de son Conseil d’Administration

January 29, 2026
Pierrick Lefranc nommé Vice-Président Exécutif Opérations Techniques et membre du Comité Exécutif

January 27, 2026
Le tribunal arbitral confirme la résiliation par Ipsen de l’accord de R&D conclu avec Galderma

January 21, 2026